Harvard Bioscience (HBIO) Cash from Operations (2010 - 2026)

Harvard Bioscience (HBIO) has 17 years of Cash from Operations data on file, last reported at 662000.0 in Q1 2026.

• On a quarterly basis, Cash from Operations fell 122.17% year-over-year to 662000.0 in Q1 2026; TTM through Mar 2026 was 3081000.0, a 1.92% increase from a year earlier, with the FY2025 full-year figure at 6729000.0, up 367.29% from the prior year.
• Cash from Operations for Q1 2026 stood at 662000.0, down from 96000.0 in the prior quarter.
• Over the last five years, Cash from Operations for HBIO reached as high as 4361000.0 in Q3 2023 and fell as low as 1986000.0 in Q1 2022.
• Historically, Cash from Operations has averaged 1334529.41 across 5 years, with a median of 1403000.0 in 2024.
• On a YoY basis, Cash from Operations climbed as much as 2189.74% in 2022 and fell as far as 291.51% in 2022.
• Year by year, Cash from Operations stood at 2679000.0 in 2022, then jumped by 60.62% to 4303000.0 in 2023, then slumped by 59.91% to 1725000.0 in 2024, then slumped by 105.57% to 96000.0 in 2025, then plunged by 589.58% to 662000.0 in 2026.
• Per Business Quant data, the three most recent Cash from Operations figures were 662000.0 in Q1 2026, 96000.0 in Q4 2025, and 1084000.0 in Q3 2025.